Related Experiment Video
Updated: Aug 17, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[WT1 peptide-based immunotherapy]
1Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine.
The Wilms' tumor gene WT1 is overexpressed in leukemia and various types of solid cancers and its product is a tumor rejection antigen. A phase I clinical trials of WT1 peptide-based cancer immunotherapy were performed with good clinical response but with only skin reaction at the injection sites of WT1 vaccine. Thus, WT1-targeting immunotherapy should be promissing.
The Wilms' tumor gene WT1 is overexpressed in leukemia and various types of solid cancers and its product is a tumor rejection antigen. A phase I clinical trials of WT1 peptide-based cancer immunotherapy were performed with good clinical response but with only skin reaction at the injection sites of WT1 vaccine. Thus, WT1-targeting immunotherapy should be promissing.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

